The company confirmed that its VANQUISH-1 and -2 trials for subcutaneous VK2735 are fully enrolled, with investigators monitoring long-term efficacy across diverse patient populations. CEO Brian Lian emphasized that the firm is also prioritizing maintenance dosing research, with results expected later this quarter. To support these clinical objectives, Viking recently appointed Dr. Hubert Chen as chief medical officer to oversee regulatory and development strategy.
In section Releases
Viking Therapeutics Advances Obesity Pipeline Amid Rising R&D Costs
Viking Therapeutics reported a net loss of $128 million for the second quarter of 2026, as the San Diego-based biotech aggressively scaled its clinical programs. The company remains focused on its lead obesity candidate, VK2735, while preparing to launch Phase 3 trials for an oral formulation later this year.
Financial statements for the quarter ending June 30, 2026, reflect the heavy investment in these trials. Research and development expenses climbed to $115.8 million, up from $60.2 million during the same period last year. Despite the burn rate, the company maintains a cash position of $502 million. Meanwhile, the pipeline continues to expand; a Phase 1 trial for the amylin receptor agonist VK3019 is now underway, marking the company’s latest attempt to broaden its metabolic disorder portfolio.
Comments (0)
No comments yet. Be the first!